How many do we miss? - Evaluation of age at onset and family history as selection criteria for genetic testing in Parkinson’s disease
Authors:
- Alexander BalckABAlexander Balck
- Eva-Juliane VollstedtEVEva-Juliane Vollstedt
- Ana WestenbergerAWAna Westenberger
- Lara M. LangeLLLara M. Lange
- Meike KastenMKMeike Kasten
- Katja LohmannKLKatja Lohmann
- Norbert BrueggemannNBNorbert Brueggemann
- Claudia TrenkwalderCTClaudia Trenkwalder
- Roy AlcalayRARoy Alcalay
- Kamalini Ghosh GalvelisKGKamalini Ghosh Galvelis
Preprint
Abstract
Importance: Current recommendations for genetic testing in Parkinson’s disease (PD) prioritize groups of patients based on age at onset (AAO) and family history (FH). The increasing importance of identifying genetic PD for personalized counseling and potential gene-specific therapies calls for a data-driven evaluation of these recommendations. Objective: To estimate the diagnostic accuracy, specifically the sensitivity, specificity, and positive predictive value (PPV), of genetic testing in PD based on AAO and FH. Design, Setting, and Participants: We analyzed data from six cohorts within four independent datasets: ROPAD, PD GENEration, the MDSGene database, the Global Parkinson’s Genetics Program (GP2), and two German observational studies. These datasets included 25,063 PD participants, of whom 6,295 carried pathogenic or likely pathogenic variants. ROPAD and PD GENEration, both prospective genetic screening studies, served as representative real-world cohorts. Main Outcome(s) and Measure(s): For each gene, we quantified the proportion of carriers by age bracket and familial vs. sporadic status. Receiver operating characteristic (ROC) curves, and area under the curve (AUC) values with 95% confidence intervals (CIs) were calculated for AAO and FH. PPVs were computed based on sensitivity, specificity, and prevalence. Results: An AAO threshold of ≤50 identified 32% (ROPAD), 23% (PD GENEration), 63% (MDSGene), and 30% (GP2) of genetic cases. ROC analyses based on AAO alone yielded AUCs of 0.59 (CI: 0.57-0.60, ROPAD), 0.58 (CI: 0.56-0.60, PD GENEration), 0.78 (CI: 0.75-0.80, MDSGene), and 0.54 (CI: 0.52-0.56, GP2), respectively. Combining AAO with FH increased AUCs to 0.60 (CI: 0.59-0.62), 0.60 (CI: 0.58-0.62), 0.83 (CI: 0.81-0.85), and 0.58 (CI: 0.56-0.60). FH improved AUCs for dominant genes such as LRRK2 (e.g., 0.52 to 0.61 in ROPAD) but had minimal or no effect for recessive genes (e.g., PRKN/PINK1 : 0.90 to 0.90 in ROPAD). Conclusions and Relevance: Current selection criteria (AAO ≤50) identify only a minority (23–32%) of variant carriers. Most carriers (68–77%) present with a later AAO and remain undetected. While AAO is moderately predictive in some cohorts, it insufficiently captures late-onset genetic forms, particularly LRRK2 -PD and GBA1 -PD. The limited incremental value of FH challenges its use as a selection criterion. These findings support revised, data-driven testing strategies to improve detection of genetic PD across all age groups. Key Points: Question: What are the diagnostic accuracy, specifically the sensitivity, specificity, and positive predictive value, of the current age at onset and family history-based selection criteria for genetic testing to identify major gene pathogenic variant carriers among patients with Parkinson’s disease? Findings: Performing genetic testing in Parkinson’s disease patients with an early age at onset ≤50 years results in a positive genetic finding in one of four patients; however, this criterion captures only 23–32% of known variant carriers in population-based datasets, underscoring its limited sensitivity and leading to substantial underdiagnosis of genetic Parkinson’s disease. The additional discriminatory value of family history is marginal. Meaning: Revised recommendations for broader genetic testing in Parkinson’s disease are warranted.Keywords
This publication has 24 references indexed in Scilit:
- Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic ReviewMovement Disorders, 2025
- Evidence‐based consensus guidelines for ALS genetic testing and counselingAnnals of Clinical and Translational Neurology, 2023
- Genetic Testing in Parkinson's DiseaseMovement Disorders, 2023
- Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD CohortMovement Disorders, 2023
- Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation CarriersAnnals of Neurology, 2022
- The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial FindingsMovement Disorders, 2020
- Genotype‐phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic reviewMovement Disorders, 2018
- Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for?Current Neurology and Neuroscience Reports, 2018
- Genotype‐Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic ReviewMovement Disorders, 2018
- Genetics of Parkinson disease2018